Unlocking the potential of
genomic medicine

Overview



Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More>>

There are no items to display.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary06/13/2018
PHILADELPHIA , June 13, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 1:00 p.m. EDT at the St.
Toggle Summary06/12/2018
- Enrollment of ASCEND trial to be increased from 42 to 64 participants - Top-line results expected during the fourth quarter 2018 PHILADELPHIA , June 12, 2018 /PRNewswire/ --   Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it will increase the sample size for Part A
Toggle Summary05/29/2018
PHILADELPHIA , May 29, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 4:30 p.m.

Recent Presentations

More >>
Date Title
06/07/2018
03/28/2018
03/16/2018
08/10/2017
05/10/2017

Upcoming Events

More >>
Date Event Details
Summary Toggle 06/20/18 at 1:00 PM EDT

Aevi Genomic Medicine, Inc. at The 2018 JMP Securities Life Sciences Conference

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Copyright Nasdaq. Minimum 15 minutes delayed.